Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
Share Facebook Twitter LinkedIn Pinterest Email Here are the highlights from Week 8 of college football, including Washington-Michigan, Ole Miss-Georgia, Utah-BYU and more.
